1975 Volume 23 Issue 6 Pages 2138-2143
The authors carried out the laboratory and clinical studies of amikacin.
The results were as follows :
The sensitivity was determined by the plate dilution method with 31 strains of Staph. aureus, 31 strains of P. aeruginosa, 26 strains of Proteus and 20 strains of E. coli isolated from patients. The growth of 93.5% of Staphylococci was inhibited at a concentraiton of less than 0.78μg/ml. The growth of 58% of P. aeruginosa was inhibited at concentration of less than 1.56μg/ml.
The growth of 92.3% of Proteus and 85% of E. coli was inhibited at a concentration of less than 6.25 μg/ml.
Amikacin was given a single intramuscular dose of 2 mg per kg. b. w. to 3 children.
The maximum blood level was reached at 30 minutes respectively after injection.
And the blood level at 6 hours after injection was 0.9 μg/ml.
The excretion rate of amikacin in the urine after a single intramuscular dosing was 42.2-61.6% up to 6 hours of period.
Amikacin was effective in 7 of 9 cases of bacterial infections.
No significant side effects were seen at all.
